TN2012000205A1 - Method and compositions for treating solid tumors and other malignancies - Google Patents
Method and compositions for treating solid tumors and other malignanciesInfo
- Publication number
- TN2012000205A1 TN2012000205A1 TNP2012000205A TN2012000205A TN2012000205A1 TN 2012000205 A1 TN2012000205 A1 TN 2012000205A1 TN P2012000205 A TNP2012000205 A TN P2012000205A TN 2012000205 A TN2012000205 A TN 2012000205A TN 2012000205 A1 TN2012000205 A1 TN 2012000205A1
- Authority
- TN
- Tunisia
- Prior art keywords
- malignancies
- compositions
- solid tumors
- treating solid
- treating
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 230000036210 malignancy Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 229940121827 Hedgehog pathway inhibitor Drugs 0.000 abstract 1
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 abstract 1
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000012636 effector Substances 0.000 abstract 1
- 229940043355 kinase inhibitor Drugs 0.000 abstract 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26234209P | 2009-11-18 | 2009-11-18 | |
| US29203210P | 2010-01-04 | 2010-01-04 | |
| PCT/US2010/056942 WO2011062939A1 (en) | 2009-11-18 | 2010-11-17 | Methods and compositions for treating solid tumors and other malignancies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TN2012000205A1 true TN2012000205A1 (en) | 2013-12-12 |
Family
ID=43384585
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TNP2012000205A TN2012000205A1 (en) | 2009-11-18 | 2012-05-07 | Method and compositions for treating solid tumors and other malignancies |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US20120232087A1 (enExample) |
| EP (1) | EP2501370A1 (enExample) |
| JP (1) | JP2013511526A (enExample) |
| KR (1) | KR20120107962A (enExample) |
| CN (2) | CN102665700A (enExample) |
| AU (1) | AU2010322114B2 (enExample) |
| BR (1) | BR112012011823A2 (enExample) |
| CA (1) | CA2781210A1 (enExample) |
| CL (1) | CL2012001271A1 (enExample) |
| IL (1) | IL219636A0 (enExample) |
| MA (1) | MA33739B1 (enExample) |
| MX (1) | MX2012005695A (enExample) |
| NZ (1) | NZ599964A (enExample) |
| PH (1) | PH12012500911A1 (enExample) |
| RU (1) | RU2012125152A (enExample) |
| TN (1) | TN2012000205A1 (enExample) |
| WO (1) | WO2011062939A1 (enExample) |
| ZA (1) | ZA201203325B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20120097512A (ko) | 2009-11-18 | 2012-09-04 | 플렉시콘, 인코퍼레이티드 | 키나제 조절을 위한 화합물 및 방법, 및 그에 대한 적응증 |
| MX349011B (es) * | 2011-06-02 | 2017-07-05 | Novartis Ag | Biomarcadores para terapia de inhibidor de hedgehog. |
| WO2013106812A1 (en) * | 2012-01-12 | 2013-07-18 | Board Of Regents, The University Of Texas System | Personalized medicine for the prediction of therapy targeting the hedgehog pathway |
| JP6293770B2 (ja) | 2012-11-05 | 2018-03-14 | ナント ホールディングス アイピー，エルエルシー | ヘッジホッグシグナル伝達経路阻害剤としての環状スルホンアミド含有誘導体 |
| CN103524535B (zh) * | 2013-10-16 | 2016-07-13 | 苏州云轩医药科技有限公司 | 具有刺猬通路拮抗剂活性的胺基噻唑-吡啶杂环化合物 |
| CA3049402A1 (en) | 2017-01-06 | 2018-07-12 | Palvella Therapeutics Llc | Anhydrous compositions of mtor inhibitors and methods of use |
| HRP20220991T1 (hr) | 2017-10-27 | 2022-11-11 | Boehringer Ingelheim International Gmbh | Derivati piridina i njihova terapeutska uporaba kao inhibitora trpc6 |
| WO2020010073A1 (en) | 2018-07-02 | 2020-01-09 | Palvella Therapeutics, Inc. | ANHYDROUS COMPOSITIONS OF mTOR INHIBITORS AND METHODS OF USE |
| WO2020061584A1 (en) * | 2018-09-21 | 2020-03-26 | Msb Holdings, Inc. | Taste-masked dosage forms |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9221220D0 (en) | 1992-10-09 | 1992-11-25 | Sandoz Ag | Organic componds |
| WO2007060404A1 (en) | 2005-11-22 | 2007-05-31 | Kudos Pharmaceuticals Limited | PYRIDO-,PYRAZO- AND PYRIMIDO-PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS |
| UA93548C2 (uk) | 2006-05-05 | 2011-02-25 | Айерем Елелсі | Сполуки та композиції як модулятори хеджхогівського сигнального шляху |
| HUE033894T2 (en) | 2006-08-23 | 2018-01-29 | Kudos Pharm Ltd | 2-Methylmorpholine pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as MTOR inhibitors |
| DK2137162T3 (en) * | 2007-03-15 | 2018-11-26 | Novartis Ag | Organic compounds and their applications |
| BRPI0812778A2 (pt) * | 2007-06-07 | 2014-12-02 | Irm Llc | Derivados de bifenilcarboxamida como moduladores da rota de hedgehog |
| CA2690378A1 (en) * | 2007-06-25 | 2008-12-31 | Amgen Inc. | Phthalazine compounds, compositions and methods of use |
| WO2009112266A1 (en) * | 2008-03-12 | 2009-09-17 | Ludwig-Maximilians-Universität | Active substance combination with gemcitabine for the treatment of epithelial cancer |
| KR101260116B1 (ko) * | 2008-04-29 | 2013-05-02 | 일라이 릴리 앤드 캄파니 | 이치환된 프탈라진 헤지호그 경로 길항제 |
| US20100041663A1 (en) * | 2008-07-18 | 2010-02-18 | Novartis Ag | Organic Compounds as Smo Inhibitors |
-
2010
- 2010-11-17 AU AU2010322114A patent/AU2010322114B2/en not_active Ceased
- 2010-11-17 CA CA2781210A patent/CA2781210A1/en not_active Abandoned
- 2010-11-17 EP EP10782767A patent/EP2501370A1/en not_active Withdrawn
- 2010-11-17 RU RU2012125152/15A patent/RU2012125152A/ru unknown
- 2010-11-17 JP JP2012539987A patent/JP2013511526A/ja not_active Ceased
- 2010-11-17 KR KR1020127015545A patent/KR20120107962A/ko not_active Withdrawn
- 2010-11-17 BR BR112012011823A patent/BR112012011823A2/pt not_active IP Right Cessation
- 2010-11-17 CN CN2010800517592A patent/CN102665700A/zh active Pending
- 2010-11-17 MX MX2012005695A patent/MX2012005695A/es not_active Application Discontinuation
- 2010-11-17 WO PCT/US2010/056942 patent/WO2011062939A1/en not_active Ceased
- 2010-11-17 PH PH1/2012/500911A patent/PH12012500911A1/en unknown
- 2010-11-17 US US13/509,857 patent/US20120232087A1/en not_active Abandoned
- 2010-11-17 NZ NZ599964A patent/NZ599964A/en not_active IP Right Cessation
- 2010-11-17 CN CN201410410334.6A patent/CN104224791A/zh active Pending
-
2012
- 2012-05-07 TN TNP2012000205A patent/TN2012000205A1/en unknown
- 2012-05-07 ZA ZA2012/03325A patent/ZA201203325B/en unknown
- 2012-05-07 IL IL219636A patent/IL219636A0/en unknown
- 2012-05-11 MA MA34856A patent/MA33739B1/fr unknown
- 2012-05-16 CL CL2012001271A patent/CL2012001271A1/es unknown
-
2014
- 2014-10-09 US US14/510,713 patent/US20150025074A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| BR112012011823A2 (pt) | 2019-09-24 |
| IL219636A0 (en) | 2012-07-31 |
| AU2010322114B2 (en) | 2014-07-31 |
| CN104224791A (zh) | 2014-12-24 |
| US20150025074A1 (en) | 2015-01-22 |
| ZA201203325B (en) | 2013-01-30 |
| CN102665700A (zh) | 2012-09-12 |
| MA33739B1 (fr) | 2012-11-01 |
| WO2011062939A1 (en) | 2011-05-26 |
| CA2781210A1 (en) | 2011-05-26 |
| US20120232087A1 (en) | 2012-09-13 |
| EP2501370A1 (en) | 2012-09-26 |
| PH12012500911A1 (en) | 2012-11-26 |
| RU2012125152A (ru) | 2013-12-27 |
| NZ599964A (en) | 2014-08-29 |
| AU2010322114A1 (en) | 2012-05-31 |
| CL2012001271A1 (es) | 2012-10-12 |
| MX2012005695A (es) | 2012-06-13 |
| KR20120107962A (ko) | 2012-10-04 |
| JP2013511526A (ja) | 2013-04-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TN2012000205A1 (en) | Method and compositions for treating solid tumors and other malignancies | |
| MX346379B (es) | Combinacion que comprende un inhibidor de cinasa 4 dependiente de ciclina o cinasa dependiente de ciclina (cdk4/6) y un inhibidor de mtor para tratar cancer. | |
| EP2139484B8 (en) | Methods of treating cancer using pyridopyrimidinone inhibitors of pi3k alpha | |
| NZ595572A (en) | Inhibitors of pi3 kinase and / or mtor | |
| MY161237A (en) | Combination therapy comprising a cdk4/6 inhibitor and a p13k inhibitor for use in the treatment of cancer | |
| SI2120932T1 (sl) | Indazolni derivati kot kinazni inhibitorji za zdravljenje raka | |
| EA201890768A2 (ru) | Лечение злокачественной опухоли ингибиторами tor-киназы | |
| MX2009006627A (es) | Quinazolinas para la inhibicion de pdk1. | |
| MX2009008132A (es) | Terapia de combinacion con inhibidores de angiogenesis. | |
| ZA200908477B (en) | Polycyclic indazole derivatives and their use as erk inhibitors for the treatment of cancer | |
| TN2012000622A1 (en) | Combinations of kinase inhibitors for the treatment of cancer | |
| JO2886B1 (en) | Useful compounds in the inhibition of CHK1 | |
| MX2015007205A (es) | Inhibidores de la desmetilasa de histona. | |
| TNSN08375A1 (en) | Quinazolines for pdk1 inhibition | |
| UA99284C2 (ru) | ИНГИБИТОРЫ р70 S6-КИНАЗЫ | |
| MX2009004214A (es) | Composiciones de inhibidores de chk1. | |
| JO2788B1 (en) | Amido phenoxyendazole compounds beneficial as C-MET inhibitors | |
| PH12015500867A1 (en) | Treatment of prostate cancer with tor kinase inhibitors | |
| JO3145B1 (ar) | مركبات مفيدة لتثبيط chk1 | |
| MX2013015357A (es) | Terapia de combinacion. | |
| MX2009008073A (es) | Inhibidores de epoxido hidrolasa solubles para el tratamiento de sindrome metabolico y trastornos relacionados. | |
| PH12014500538A1 (en) | Methods and compositions for treating leukemia | |
| MX2011008069A (es) | Uso de inhibidores de topoisomerasa i para tratar el cancer. | |
| AP2011005893A0 (en) | Thia-triaza-cyclopentazulenes as P13-kinases inhibitors for the treatment of cancer. | |
| TN2011000013A1 (en) | Amidophenoxyindazoles useful as inhibitors of c-met |